1. Home
  2. CGEN vs SPPP Comparison

CGEN vs SPPP Comparison

Compare CGEN & SPPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CGEN
  • SPPP
  • Stock Information
  • Founded
  • CGEN 1993
  • SPPP 2011
  • Country
  • CGEN Israel
  • SPPP Canada
  • Employees
  • CGEN N/A
  • SPPP N/A
  • Industry
  • CGEN Biotechnology: Biological Products (No Diagnostic Substances)
  • SPPP
  • Sector
  • CGEN Health Care
  • SPPP
  • Exchange
  • CGEN Nasdaq
  • SPPP NYSE
  • Market Cap
  • CGEN 142.8M
  • SPPP 139.1M
  • IPO Year
  • CGEN 2000
  • SPPP N/A
  • Fundamental
  • Price
  • CGEN $1.60
  • SPPP $9.07
  • Analyst Decision
  • CGEN Strong Buy
  • SPPP
  • Analyst Count
  • CGEN 2
  • SPPP 0
  • Target Price
  • CGEN $4.00
  • SPPP N/A
  • AVG Volume (30 Days)
  • CGEN 445.1K
  • SPPP 275.9K
  • Earning Date
  • CGEN 11-12-2024
  • SPPP 01-01-0001
  • Dividend Yield
  • CGEN N/A
  • SPPP N/A
  • EPS Growth
  • CGEN N/A
  • SPPP N/A
  • EPS
  • CGEN 0.02
  • SPPP N/A
  • Revenue
  • CGEN $59,852,000.00
  • SPPP N/A
  • Revenue This Year
  • CGEN $57.27
  • SPPP N/A
  • Revenue Next Year
  • CGEN N/A
  • SPPP N/A
  • P/E Ratio
  • CGEN $88.75
  • SPPP N/A
  • Revenue Growth
  • CGEN 698.03
  • SPPP N/A
  • 52 Week Low
  • CGEN $1.35
  • SPPP $8.55
  • 52 Week High
  • CGEN $3.03
  • SPPP $11.39
  • Technical
  • Relative Strength Index (RSI)
  • CGEN 51.01
  • SPPP 31.74
  • Support Level
  • CGEN $1.55
  • SPPP $9.22
  • Resistance Level
  • CGEN $1.68
  • SPPP $9.37
  • Average True Range (ATR)
  • CGEN 0.08
  • SPPP 0.12
  • MACD
  • CGEN 0.01
  • SPPP -0.02
  • Stochastic Oscillator
  • CGEN 52.17
  • SPPP 2.28

About CGEN Compugen Ltd.

Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902, bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.

About SPPP SPROTT PHYS PLATINUM & PALLADIUM

Sprott Physical Platinum & Palladium Tr invests and holds all of its assets in physical platinum and palladium bullion. The company seeks to provide a secure, convenient, and exchange-traded investment alternative for investors interested in holding physical platinum and palladium bullion without the inconvenience that is typical of a direct investment in physical bullion. The Trust invests mainly in long-term holdings of unencumbered, fully allocated, physical platinum and palladium bullion.

Share on Social Networks: